CliffBio
small molecule

NYSTATIN

NYSTATIN

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameNYSTATIN
Active ingredientNYSTATIN
Strength100,000 UNITS/GM
Dosage formPOWDER
RouteTOPICAL
ModalitySmall molecule
FDA approvalJuly 2004
Marketing statusRX

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.